Edwards Lifesciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
π Edwards Lifesciences reported third-quarter sales of USD 1,715.5 million, an increase from USD 1,553.1 million in the prior-year quarter.
π° Net income for the third quarter rose to USD 307.5 million compared to USD 291.1 million a year ago.
π Basic and diluted earnings per share from continuing operations were USD 0.53, up from USD 0.50 in the previous year's quarter.
π Nine-month sales reached USD 5,105.1 million, surpassing the prior-year total of USD 4,498 million.
β οΈ Net income for the nine months declined to USD 930.1 million compared to USD 982.3 million a year ago.
π Basic earnings per share from continuing operations for the nine-month period decreased to USD 1.61 from USD 1.70.
Bullish Signals
- Edwards Lifesciences achieved third-quarter sales growth, reporting USD 1,715.5 million in revenue compared to USD 1,553.1 million a year ago.
- The company posted an increase in net income for the third quarter, reaching USD 307.5 million versus USD 291.1 million in the prior-year period.
- Earnings per share from continuing operations improved in the third quarter to USD 0.53, up from USD 0.50 a year ago.
Risk Factors
- Net income for the nine months ended September 30, 2026, declined to USD 930.1 million compared to USD 982.3 million in the prior-year period.
- Basic earnings per share from continuing operations decreased to USD 1.61 for the nine-month period, down from USD 1.70 a year ago.
Full Analysis
Edwards Lifesciences Corporation reported its financial results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company generated sales of USD 1,715.5 million, representing an increase from USD 1,553.1 million in the same period last year. Net income rose to USD 307.5 million compared to USD 291.1 million a year ago, while basic and diluted earnings per share from continuing operations both reached USD 0.53, up from USD 0.50 in the prior-year quarter.
Over the nine-month period ending September 30, 2026, Edwards Lifesciences achieved total sales of USD 5,105.1 million, a significant increase from USD 4,498 million reported for the same timeframe in the previous year. However, net income for the nine months decreased to USD 930.1 million compared to USD 982.3 million a year ago. Consequently, basic earnings per share from continuing operations fell to USD 1.61 from USD 1.70, and diluted earnings per share dropped to USD 1.61 from USD 1.67 during the nine-month period.